Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions
Authors:
- Roberta BruhnRBRoberta Bruhn
- Nico LelieNLNico Lelie
- Steven KleinmanSKSteven Kleinman
- the International NAT Study GroupTGthe International NAT Study Group
- 27 February 2015
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 55 (6) , 1195-1205
Abstract
The relative contribution of serologic screening and nucleic acid testing (NAT) to prevent hepatitis C virus (HCV) transmission has not been rigorously addressed.Twenty-one blood organizations in seven geographical regions performing individual-donation (ID)-NAT in parallel with anti-HCV screening provided data from 10,897,105 donations to establish HCV infection rates in first-time, lapsed, and repeat donations. Screening efficacy was modeled for: anti-HCV alone, HCV antigen/antibody (combo), minipool (MP)-NAT in pools of 8 and 16 with anti-HCV, ID-NAT and anti-HCV, and ID-NAT alone. Probabilities of infectivity for red blood cell transfusions were estimated as 100% from window period (WP) and concordant HCV RNA/antibody-positive (concordantly positive [CP]) donations and 0.028% from anti-HCV-positive and RNA-negative probable resolved (PR) donations.There were 5146 confirmed infections (30 WP, 3827 CP, and 1289 PR). Infection rates and transmission risks varied substantially across regions and by donation status. Residual risk with ID-NAT and serology screening was estimated at one in 250,000 in Egypt and at one in 10,000,000 in other regions combined; risk would increase to one in 7300 and one in 312,000, respectively, if NAT had not been performed. ID-NAT with or without anti-HCV testing showed higher efficacy than either MP-NAT or combo assays, particularly in lapsed or repeat donors in whom 99.2, 98.5, and 93.2% of infectious donations were estimated to be interdicted by these respective testing strategies.The incremental efficacy of anti-HCV testing when ID- NAT screening is performed was minimal, particularly for screening lapsed and repeat donations.Keywords
Funding Information
- Grifols Diagnostics, Inc.
This publication has 14 references indexed in Scilit:
- Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenariosTransfusion, 2015
- Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003–2010Digestive Diseases and Sciences, 2014
- Estimating window period blood donations for human immunodeficiency virusType 1, hepatitis Cvirus, and hepatitis Bvirus by nucleic acid amplification testing in SouthernPakistanTransfusion, 2014
- Prevalence of human immunodeficiency virus RNA and antibody in first‐time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenariosTransfusion, 2013
- International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009Vox Sanguinis, 2011
- Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithmsTransfusion, 2010
- Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusionTransfusion, 2009
- Dynamics of viremia in early hepatitis C virus infectionTransfusion, 2005
- A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donorsTransfusion, 2005
- Titration of Hepatitis C Virus in Chimpanzees for Determining the Copy Number Required for TransmissionIntervirology, 2004